Adrenal Cancer
8
2
2
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
12.5%
1 terminated out of 8 trials
75.0%
-11.5% vs benchmark
0%
0 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma
Assessment of Metabolic Complications in Patients With Adrenal Tumors Through Radiological Images
The Registry of Oncology Outcomes Associated with Testing and Treatment
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
A Pilot Study of F-18 Paclitaxel (FPAC) PET for Evaluating Drug Delivery of Solid Tumors in Breast, Lung, Renal, and Adrenal Cancers
Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
Salivary Free Cortisol Response to Cosyntropin Stimulation Test in Mitotane Treated Patients
Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma